Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

Volume 45, no. 4, p. 1086–1093, 2001. Page 1090, column 1, lines 1 to 5: “did not show any … or its metabolites” should read “showed no significant differences in exposure to either the parent drug or its metabolites between the first dose and steady state (Table 3); however, this analysis was not designed or powered to rule out modest changes in clearance or exposure, and the trend for increased M8-to-nelfinavir concentration ratio on day 28 may reflect modest induction of metabolism during multiple dosing.”